Katherine Scilla, MD
Internal Medicine · Baltimore, MDNPI 1992020457
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Daiichi Sankyo Inc. accounts for 81.3% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $1,556, more than ten times the $34 reported in 2019.
Across 11 payments — averaging $154.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1K
- Mirati Therapeutics, Inc.$112
- Galvanize Therapeutics, Inc$88
- AbbVie$86
- Novartis$34
Across 80 payments — averaging $6528.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$172K
- Merck$123K
- AstraZeneca$89K
- Astrazeneca UK Limited$44K
- Daiichi Sankyo Inc.$33K
- AbbVie$23K
- plus $39K from 4 others
What the payments were for
- Speaking & faculty fees$1,00059%
- Travel & lodging$36421%
- Food & beverage$33820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 4 | $1,383 |
| Mirati Therapeutics, Inc. | 1 | $112 |
| Galvanize Therapeutics, Inc | 1 | $88 |
| AbbVie | 3 | $86 |
| Novartis | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRAZATI$112
How this compares
$1,701 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 43 | $675,047 |
| Prochlorperazine Maleate | 32 | $557 |
| Ondansetron Hcl | 30 | $330 |
| Dexamethasone | 24 | $246 |
| Oxycodone Hcl | 14 | $155 |
| Olanzapine | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Julie PaikBaltimore$76K
- Allison AgwuBaltimore$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.